← ANALYST RATINGS · TIPRANKS
Adaptive Biotechnologies (ADPT): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy1 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $31.07, the highest $35.00, the lowest $27.00. The average is +29.4% from the last price of $24.02.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $27.00 → $30.00+11.1% | Buy | +24.9% | Reiterated | 14.10.26on TipRanks 06:10 | +2.4%next day −0.4% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $22.00 → $27.00+22.7% | Hold | +12.4% | Reiterated | 13.10.26on TipRanks 08:55 | −1.1%next day +2.4% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $28.00 → $32.00+14.3% | Buy | +33.2% | Reiterated | 13.10.26on TipRanks 08:41 | −1.1%next day +2.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $31.00 → $30.00−3.2% | Hold | +24.9% | Downgrade | 03.10.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $30.00 → $29.00−3.3% | Hold | +20.7% | Reiterated | 03.10.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $32.00 → $31.00−3.1% | Hold | +29.1% | Downgrade | 03.10.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $30.00 → $29.00−3.3% | Hold | +20.7% | Reiterated | 03.10.26on TipRanks 01:05 | — | |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $25.00 → $32.00+28.0% | Buy | +33.2% | Reiterated | 01.10.26on TipRanks 08:30 | −5.5%next day +2.8% · 5 days −6.0% | ↗ |
| Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% | Goldman Sachs | $35.00 | Buy | +45.7% | Initiated | 29.09.26on TipRanks 07:20 | +1.1%next day +0.7% · 5 days −8.4% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $30.00 → $29.00−3.3% | Hold | +20.7% | Reiterated | 29.09.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $30.00 → $29.00−3.3% | Hold | +20.7% | Reiterated | 29.09.26on TipRanks 01:05 | — | |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $25.00 → $34.00+36.0% | Buy | +41.5% | Reiterated | 22.09.26on TipRanks 06:05 | +0.7%next day +0.1% · 5 days +3.7% | ↗ |
| William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% | Craig-Hallum | — | Buy | — | Reiterated | 17.09.26on TipRanks Sep 18 07:30 | +2.0%next day +0.1% · 5 days +2.7% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $27.50 | Buy | +14.5% | Reiterated | 24.08.26on TipRanks 10:00 | −1.4%next day +2.4% · 5 days −2.9% | ↗ |
| Sebastian Sandler★★★★★★★★★★#4618 · hits 100% · avg +46.7% | J.P. Morgan | $25.00 → $27.00+8.0% | Buy | +12.4% | Reiterated | 30.07.26on TipRanks 09:26 | +5.5%next day −7.4% · 5 days −6.0% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Reiterated | 30.07.26on TipRanks 05:55 | +5.5%next day −7.4% · 5 days −6.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Adaptive Biotechnologies
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $29.36 at a price of $28.90 (+1.6%); now: $31.07 at $24.02 (+29.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Buy | 7 | 9 | 18 | 13 | 14 | 8 |
| Hold | 1 | 1 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.09 (from $-0.11 to $-0.06). Last quarter: $-0.25.
Sales
Next quarter’s sales estimate — $72M (from $70M to $73M). Last quarter: $72M.
Best top-analyst consensus in the sector · Healthcare
About Adaptive Biotechnologies
- CEO: Chad Robins
- Employees: 624
- 1165 Eastlake Avenue East, Seattle, WA, 98109, US
- www.adaptivebiotech.com
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Data from the stock’s TipRanks forecast page, read 29 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗